Canada Clinical Diagnostics Market Sample Report 2022 to 2030

Canada Clinical Diagnostics Market
Analysis
A sample report on

This report presents a strategic analysis of the Canada Clinical
Diagnostics Market and a forecast for its development in the medium
and long term. It provides a comprehensive overview of the market
value, dynamics, segmentation, main players, growth and demand
drivers, challenges & future outlook, etc. This is one of the most
comprehensive reports about the Canada Clinical Diagnostics
Market, and offers unmatched value, accuracy, and expert insights.

3
A Sample Report on Canada Clinical Diagnostics Market Analysis I Confidential
Report Scope
Report Attribute Details
Number of Pages 70-80
Base Year for Estimation 2022
Forecast Period 2023-2030
Report Coverage
Market Overview, Revenue Forecast, Market Segmentation, Growth Factors and Trends,
Competitive Landscape, Key Company Profiles, Government Policies, Regulatory Landscape,
Reimbursement Scenario
Quantitative Units Revenue in USD Million/Billion (Mn/Bn)
Research Approach Secondary Research (60%), Primary Research (40%)
Click on the icon to know the detailed methodology

4
Table of Content
CONTENT PG. NO.
1. Clinical Diagnostics Overview 12-25
1.1. Overview
1.2. Canada Overview
1.3. Economic Overview: Canada
1.4. Clinical Diagnostics Market in Canada
1.5. Healthcare Services Market in Canada
1.6. Healthcare Scenario in Canada
1.7. Health Insurance Coverage: Canada
1.8. Budget of the Government for Public Insurance
1.9. Mergers and Acquisitions
2. Market Size and Forecasting 26-31
2.1 Market size and forecasts (Excel and Methodology)
2.2. Market Segmentation

5
Table of Content
CONTENT PG. NO.
2.2.1. By Test
2.2.2. By Product
2.2.3. By End User
3. Types of Clinical Diagnostics Test 32-37
3.1 Laboratory Test
3.2 Imaging Test
3.3 Molecular Diagnostics
3.4 Point-Of-Care Testing
4. Market Dynamics 38-42
4.1. Market Growth Drivers
4.1.1. Increasing Prevalence of Health Morbidities like Cancer, Chronic & Infectious Diseases
4.1.2. Growing awareness about early detection & screening of diseases
4.1.3. Government initiatives and investments in increasing number of equipment in diagnostic
facility

6
Table of Content
CONTENT PG. NO.
4.2. Market Restraints
4.2.1. Delayed in Diagnosis
4.2.2. Shortage of Diagnosis Equipment
4.2.3. Data Privacy Concerns 43-53
5. Competitive Landscape
5.1. Major Market Share
5.2. Key Company Profile
5.2.1. Dynacare
5.2.1.1. Overview
5.2.1.2. Product Applications & Services
5.2.1.3. Recent Developments
5.2.1.4. Partnerships Ecosystem
5.2.1.5. Financials (Based on Availability)

7
Table of Content
CONTENT PG. NO.
5.2.2. LifeLabs Medical Laboratory Services
5.2.2.1. Overview
5.2.3. SickKids
5.2.3.1. Overview
5.2.4. MIC Medical Imaging

8
Table of Content
CONTENT PG. NO.
5.2.4.1. Overview
5.2.5. Public Health Ontario
5.2.5.1. Overview
5.2.6. Biron
5.2.6.1. Overview

9
Table of Content
CONTENT PG. NO.
5.2.7. Akumin Inc
5.2.7.1. Overview
5.2.8. AlphaLabs
5.2.8.1. Overview

10
Table of Content
CONTENT PG. NO.
5.2.9. EFW Radiology
5.2.9.1. Overview
5.2.10. Spartan Bioscience:
5.2.10.1. Overview

11
Table of Content
CONTENT PG. NO.
6. Reimbursement Scenario 54-60
6.1. Reimbursement Regulation
6.2. Reimbursement Process for Diagnosis
6.3 Reimbursement Process – Medicare
6.4 Reimbursement Process – Medicaid
7. Methodology & Scope 61-67

Canada Clinical Diagnostics Market Analysis
1. Clinical Diagnostics Overview

13
1.1 Statistics at a Glance: Status of Clinical Diagnostics in the World
Prevalence of Clinical Diagnostics  Please be aware that this sample report is
intended to provide you with a brief
overview of the kind of information and
analysis that will be presented in the final
report
 In this section you will get an
understanding of the topic, which includes
the prevalence of the disease, the
application of medical devices, new
technology, and other details related to the
topic
 In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
 Final report will be comprehensive and
detailed, and it will include data, analysis,
trends, and other relevant information
related to the topic or subject matter of
interest
$76.2 Bn
Was the market size of Global
Clinical Diagnostics in 2022
8.56%
Can be the exhibiting CAGR of
the Clinical Diagnostics Market
from 2022-2028
$7 Bn/year
Is the amount saved using the health apps by monitoring and diagnosing
health condition associated with diabetes prevention and care, asthma, and
cardiac and pulmonary rehabilitation
17-20%
Is the expected increase in
revenue of the diagnostic
companies
55%
Of the most downloaded
clinically rated apps are linked
to biosensors

14
1.1 Statistics at a Glance: The Status of Clinical Diagnostics in the World
(continued)
North America
~ Market Size of
$xx Bn
Europe
~Revenue to reach
$xx Bn by 2027
Asia
-Has the Fastest
CAGR of xx %
Africa
~Market Size of $xx
Bn
Canada Market
~$xx Mn
Illustrative

15
1.2 Canada Overview
38.45 Mn
Is the population of
Canada, in 2022
41 years
Is the median age
in Canada, in 2022
$1.99 Tn
Is the Gross
Domestic Product
(GDP) in Canada in
2021
$8019
per capita was the
amount of national
health expenditures in
2021
 Please be aware that this sample report is
report
understanding of the demographics of the
country/region, which includes the
population, GDP, healthcare expenditure
and other details related to the topic
interest

16
1.3 Economic Overview: Canada
XX
XX
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F
Population of Canada, (2020-2030)
XX
XX
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F
GDP of Canada, (2020-2030)
Population Split (2023)
55-64
0-14
15-24
25-54
65+
Male
49%
Female
51%
By Age Group
By Gender
 In this section you will get an understanding of the demographics
of the country/region, which includes the population, GDP,
healthcare expenditure and other details related to the topic
 In order to obtain access to all of the information that you are
seeking, you will need to purchase the final report
 Final report will be comprehensive and detailed, and it will
include data, analysis, trends, and other relevant information
related to the topic or subject matter of interest
Illustrative

17
1.4 Statistics at a Glance: Glance at Canada Clinical Diagnostics Market
 Please be aware that this sample report
is intended to provide you with a brief
analysis that will be presented in the
final report
understanding of the topic, which
includes the prevalence of the disease,
the application of medical devices, new
technology, and other details related to
the topic in Canada
information that you are seeking, you
will need to purchase the final report
detailed, and it will include data,
analysis, trends, and other relevant
information related to the topic or
subject matter of interest
$3.9 Bn
Was the market size of
Canada Clinical Diagnostics
Market in 2022
3.1%
Is the expected CAGR of the
Canada Clinical Diagnostics
Market for period of 2022-
2030
90%
Is the rate of approval for the in-vitro diagnostics test application submitted
for getting the diagnostic test done in Canada
7,307
Is the number of medical and
diagnostic laboratory
companies are present in
Canada
50 to 82 days
Is the average waiting period
for CT scans in Canada

18
1.5 Healthcare Services in Canada
xx xx xx xx xx xx xx xx xx
2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Canada Healthcare Services Market Forecast, 2022-2030 (in $Bn)
 Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be
presented in the final report
 In this section you will get an understanding of the overall Healthcare Services market in Canada, which includes the market size, current
trends and other details related to the topic
 In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
 Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or
Illustrative

19
1.6 Healthcare Scenario in Canada
Clinical diagnostics Process: The process of developing a clinical diagnostics drug is complex and involves many stages, from preclinical
research to clinical trials to regulatory approval. Here is a simplified diagram of the clinical diagnostics drug development process:
o Preclinical Research: Researchers identify potential drug candidates and test them in the lab
o Phase 1 Clinical Trials: Small studies are conducted to test the safety and dosage of the drug in humans
o Phase 2 Clinical Trials: Larger studies are conducted to test the effectiveness of the drug in treating clinical diagnostics
o Phase 3 Clinical Trials: Even larger studies are conducted to compare the new drug to standard treatments and evaluate its safety and
effectiveness
o Regulatory Approval: The drug is reviewed by regulatory agencies such as the FDA and approved for use in the US market
Fast Track
 Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat
serious conditions and fill an unmet medical need
Breakthrough
Therapy
 A process designed to expedite the development and review of drugs which may demonstrate substantial
improvement over available therapy
Accelerated
Approval
 These regulations allowed drugs for serious conditions that filled an unmet medical need to be approved
based on a surrogate endpoint
Priority Review  A Priority Review designation means FDA’s goal is to take action on an application within 6 months
FDA has developed several approaches to making drugs available as quickly as possible, while still ensuring their safety and
effectiveness. Here are four of these approaches:
Illustrative

20
1.6 Healthcare Scenario: Diagnostic Process Patient Journey
Patient
Physician
Laboratory Test/Imaging
Test/Molecular Diagnostic
Pathologist/Radiologist
Patient sees family
doctor or specialist
Pathologist/Radiologist produces
a report and sends it to referring
physician
Report contains summary of
findings, possible diagnoses,
and recommended next steps
Next Step
Based on the radiologist's report,
the referring physician decides on
the next steps for patient
Physician sends patient
for medical imaging
Results get sent to pathologist/
radiologist for review and analysis

21
1.7 Health Insurance Coverage: Canada
26
12
20
Supplementary Health
Disability
Accident & other
There are four main types of health insurance in Canada:
 Public insurance
 Private local insurance
 International insurance
 Travel insurance
Public insurance offers free healthcare. Eligibility and coverage differ among provinces. To be eligible
for public insurance in Canada, you need to be physically present in Canada for over 183 days
Out of 37.5 Mn citizens, most are insured by the government, yet 25 Mn Canadians have opted for
additional insurance
For public insurance, the cost of health insurance will be paid indirectly through your tax. On
average, 10% of your income will go to public insurance
Local private insurance can cost around $100-$200 a month, while international insurance costs
around $200-$300 a month
Coverage Type 2020 2021 Change %
Total 327,521 328,074
Any health plan 299,230 300,887 0.4
Any private plan 217,896 216,366 –0.6
Employment-based 178,737 178,285 –0.2
Direct-purchase 33,869 33,555 –0.1
Marketplace coverage 10,924 11,389 0.1
TRICARE 9,165 8,299 –0.3
Any public plan 112,925 117,095 1.2
Medicare 58,541 60,226 0.5
Medicaid 58,778 61,940 0.9
VA and CHAMPVA 2,967 3,151 0.1
Uninsured 28,291 27,187 –0.4
Number of people with health insurance in Canada in 2020, by coverage
type (in Mn)
Number of People By Health Insurance
Coverage
(for illustrative purpose)
Illustrative

22
1.8 Budget of Canada Government for Public Insurance
Proposed Budget By Category
Outlays 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2022-31
In Billions Of Dollars
Medicare $769 $709 $766 $841 $840 $947 $1,014 $1,085 $1,227 $1,178 $1,325 $1,412 $10,633
Medicaid $458 $521 $571 $582 $616 $645 $674 $698 $734 $768 $801 $837 $6,926
As % Of GDP
Medicare 3.7% 3.2% 3.3% 3.4% 3.3% 3.6% 3.7% 3.8% 4.1% 3.8% 4.1% 4.2% 3.7%
Medicaid 2.2% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.5% 2.5% 2.5% 2.5% 2.4%
 National Health Expenditures (NHE) grew 2.7% to $4.3 trillion in 2021, or $12,914 per person, and accounted for 18.3% of Gross Domestic Product (GDP)
 Medicare spending grew 8.4% to $900.8 billion in 2021, or 21% of total NHE
 Medicaid spending grew 9.2% to $734.0 billion in 2021, or 17% of total NHE
 Private health insurance spending grew 5.8% to $1,211.4 billion in 2021, or 28% of total NHE
 Out of pocket spending grew 10.4% to $433.2 billion in 2021, or 10% of total NHE
 Other Third Party Payers and Programs and Public Health Activity spending declined 20.7% in 2021 to $596.6 billion, or 14% of total NHE
 Hospital expenditures grew 4.4% to $1,323.9 billion in 2021, slower than the 6.2% growth in 2020
 Physician and clinical services expenditures grew 5.6% to $864.6 billion in 2021, slower growth than the 6.6% in 2020
 Prescription drug spending increased 7.8% to $378.0 billion in 2021, faster than the 3.7% growth in 2020
 Largest shares of total health spending were sponsored by the federal government (34%) and the households (27%). The private business share of health
spending accounted for 17% of total health care spending, state and local governments accounted for 15%, and other private revenues accounted for 7%
Illustrative

23
1.9 Mergers and Acquisitions
$6.0
$7.7
$10.5
$16.7
$6.8
$11.7
1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022
82
112 107 107
89
110
1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022
57% of the total deal volume are done by strategic buyers and the rest 43% are done by financial buyers in 2020
RCM M&A Deal Value Trend ($Bn) RCM M&A Deal Volume Trend
Buyer Composition: Strategic Vs Financial (2020)
59%
41% 41%
59% 58%
42%
61%
39%
$0- $25 $25-$50 $50-$100 $100+
Strategic Buyers
Financial Buyers
Buyer Type by Deal Size
($Mn)
Illustrative

24
1.9 Mergers and Acquisitions (continued)
Latest Deals In Canada
Company Key Insights
 In February 2023, The Clinical and Laboratory Standards Institute (CLSI) awarded PHO's laboratory
the 2023 Excellence in Member Organization Leadership Award
 PHO assumed leading role in the Ontario COVID-19 Genomics Network and the COVID-19 Testing
Strategy Expert Panel, in addition to participation in the COVID-19 Provincial Diagnostic Network in
Ontario
 In December 2022, Biron Health Group's medical biology laboratory received a certification from the
Standards Council of Canada for the ISO 15189 standard Medical labs - Requirements for quality and
competence, after a conformity evaluation by the “Bureau de normalization du Québec”
 MIC has been an important provider of health care services in Northern Alberta, running 13
community-based imaging clinics and supplying contract services to 12 Edmonton area hospitals and
community health centers
 In September 2021, PocketHealth, the creator of healthcare's most innovative digital image sharing
solution, announced how MIC Medical Imaging opted its platform to make diagnostic image sharing
more accessible for patients

25
1.9 Mergers and Acquisitions (continued)
Latest Deals In Canada
Company Key Insights
 Merger details
Merger  Acquisition details
Illustrative

2. Market Size and Forecasting

27
2.1 Market size and forecasts (Excel and Methodology)
XX
XX
2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Canada Clinical Diagnostics Market Forecast, 2022-2030 (in $Bn)
 Please be aware that this sample report
is intended to provide you with a brief
analysis that will be presented in the
final report
understanding of the overall Healthcare
Insurance market in Malaysia, which
includes the market size, current trends
and other details related to the topic
information that you are seeking, you
detailed, and it will include data,
analysis, trends, and other relevant
information related to the topic or
Click on the icon to know the
methodology and assumption
2023 2024 2025 2026 2027 2028 2029 2030
Major Markets Patient (Mn) 2.74 2.82 2.90 2.94 2.98 3.02 3.07 3.12
Canada Patient Size (Bn) 0.51 0.61 0.68 0.69 0.70 0.71 0.72 0.73
% of US Patients 18.75% 21.70% 23.56% 23.45% 23.42% 23.39% 23.34% 23.45%
Global Market Size (Bn $) 3,620 3,780 3,950 4,128 4,314 4,508 4,711 4,937
Canada Market Size (Bn $) 61 74 84 87 91 95 99 106
Illustrative

28
2.2 Snapshot of Clinical Diagnostics Market Segmentation
 In this section you will get an understanding of the segmentations which will cover the Canada Clinical Diagnostics Market
 In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
Lipid Panel
Liver Panel
Instruments
Reagents
Others
By End-User
Hospital Laboratory
Diagnostic Laboratory
By Test
Renal Panel
Complete Blood Count
Electrolyte Testing
Infectious Disease Testing
Others
By Product
Point-of-care Testing
Others

29
Canada Clinical Diagnostics Market Share, By Test (2022)
Lipid Panel
Liver Panel
Renal Panel
Complete Blood
Count
Electrolyte
Testing
Infectious
Disease Testing
Others
 Lipid Panel market in Canada is a significant
component of the overall clinical diagnostics
treatment market
 It has the maximum market share in Canada
clinical diagnostics market with
approximately xx%
intended to provide you with a brief overview
of the kind of information and analysis that
will be presented in the final report
trends, and other relevant information related
to the topic or subject matter of interest
2.2.1 Market Segmentation: By Test
Illustrative

30
Canada Clinical Diagnostics Market Share, By Product (2022)
Instruments
Reagents
Others
2.2.2 Market Segmentation: By Product
 Instruments clinical diagnostics market in
Canada is a significant component of the
overall clinical diagnostics market
 It has the maximum market share in Canada
clinical diagnostics market with
approximately xx%
Illustrative

31
Canada Clinical Diagnostics Market Share, By End User (2022)
Hospital
Laboratory
Diagnostic
Laboratory
Point-of-care
Testing
Others
2.2.3 Market Segmentation: By End User
 Hospital Laboratories have the maximum
market share in Canada clinical diagnostics
market with approximately xx%
Illustrative

3. Types of Clinical Diagnostics Test

33
3.1 Laboratory Test
Top most commonly ordered laboratory tests in Canada
The data presented here includes over 51 commonly ordered laboratory tests by percentage in Canada (Appendix 3)
Complete blood count Creatinine
Thyroid stimulating hormone Electrolyte panel
Alanine amino-transferase Hemoglobin A1c
LDL cholesterol Ferritin
Urinalysis with microscopic Others
Community
Complete blood count Electrolyte panel
Creatinine Magnesium
Phosphate Scan with morphology
Urea Prothrombin time (INR)
Calcium Others
Inpatient
Complete blood count Chem panel 7
Creatinine Electrolyte panel
Liver panel Troponin-T
Prothrombin time (INR) Urinalysis with microscopic
Blood culture Others
Emergency

34
3.2 Imaging Test
 Imaging tests in Canada include: X-rays, CT (Computed Tomography) scans, MRI (Magnetic Resonance Imaging) scans
Ultrasound, PET (Positron Emission Tomography) scans, Nuclear imaging & Mammogram
 In 2022, it was estimated that 28,600 Canadian women will be diagnosed with breast cancer ultimately raising the demand
for Mammography Imaging as well as services
 In August 2022, through a collaboration with Synthesis Health, Pelican Narrows and two additional Peter Ballantyne Cree
Nation (PBCN) towns, Deschambault Lake and Southend, the first ultra portable X-ray equipment was installed in Canada
Imaging Test 2017 2020 2030
Computed Tomography Scan (CT) in Mn XX XX XX
Magnetic Resonance Imaging (MRI) in Mn
XX XX XX
Positron Emission Tomography (PET) in Mn XX XX XX
Number of diagnostics expected to be performed in Canada (in Mn)

35
3.3 Molecular Diagnostics
Molecular diagnostic tests are laboratory tests that employ molecular biology techniques to detect particular genetic
material (DNA or RNA) or protein or other molecule linked with a condition or disorder from the sample of tissue, blood, or
other body fluids
Polymerase chain reaction (PCR)
Real-Time RT-PCR
Next-generation sequencing (NGS)
In-situ hybridization (ISH)
Fluorescence In-Situ Hybridization (FISH)
Chromogenic in situ hybridization (CISH)
Immunohistochemistry
Array-based comparative genomic
hybridization
Molecular Diagnostic methods Molecular Diagnostics applications
Oncology ( BRCA1, BRCA2, HER2, EGFR,
KRAS)
Infectious diseases (SARS-CoV-2,Flu A/B &
RSV)
Inherited genetic disorders (cystic fibrosis,
sickle cell anaemia, down's syndrome and
Huntington's disease)
Disease progression monitoring
Personalized medicine formulation
Reproductive Testing – Non-invasive
Prenatal Tests (NIPT), IVF, New born
screening

36
Key Insights
3.4 Point-Of-Care Testing
POC Diagnostics Market Share By Indication
Hematology Testing
Cardiometabolic Diseases
Others
Pregnancy & Infertility
Testing
Infectious Diseases
Blood Glucose Monitoring
 Increased prevalence of diabetes and cancer, the use of novel
point-of-care diagnostics, and the preference for at-home
glucose testing all contribute to the expansion of the blood
glucose monitoring market
 8.9% of the population of Canada, or more than 3 Mn people,
have diabetes, and after accounting for population ageing over
time, the prevalence has been rising at an average rate of
3.3% each year
 Considerable risk of acquiring type 2 diabetes is also posed by
the 6.1% prevalence of prediabetes in Canadian adults
 On the other side, the category for infectious disorders is
expected to develop at the quickest rate
 Market segment for infectious diseases is anticipated to
expand significantly over the forecast period due to the rising
prevalence of various infectious disorders
Other*- Hyperthyroidism, Oxygen Testing, assessment for developing contrast-
induced nephropathy (CIN), Colorectal cancer screening, Dipstick urinalysis

37
3.4 Point-Of-Care Testing (continued)
This policy applies to This policy does not apply to
Test Settings
 All community-based point-of-care settings where POCT is
provided or deployed (e.g., a clinic, physician's office, pharmacy,
or long-term care facility outside of a health authority)
 Virtual care settings (i.e., where an individual consults virtually
with a health-care provider)
 Facilities that are health authority governed or subject to the
CPSBC’s accreditation programs
 POCT provided as direct-to-consumer testing
Type of
Testing
 POCT involving biologic specimens  POCT that does not involve the testing of biologic specimens
(e.g., measurements using a blood pressure cuff, or instruments
to measure weight, height, and temperature)
 Diagnostic imaging or screening services administered under
the Medicare Protection Act
Self-Testing
 Self-testing under guidance by a health-care provider at the time
of testing (i.e., guided self-testing)
 Self-testing and direct-to-consumer testing
Community-based point-of-care testing policy (British Columbia)
British Columbia Ministry of Health (the Ministry) regulates and influences the provision and utilization of POCT in particular
medical/clinical domains through accreditation standards for diagnostic service providers and scope of practice regulations that specify
which healthcare professionals are allowed to perform tests, interpret results, make diagnoses, and manage treatments. This is done
to ensure the quality and safety of care in these settings
Scope:

4. Market Dynamics

39
4.1 Market growth drivers
 Incidence of diseases is increasing in Canada, with more than 1.8 Mn new
clinical diagnostics cases expected to be diagnosed in 2023
 This is driving the demand for clinical diagnostics treatments and creating
opportunities for growth in the clinical diagnostics market
 Please be aware that this sample report is intended to provide you with a
brief overview of the kind of information and analysis that will be presented
in the final report
 In order to obtain access to all of the information that you are seeking, you
 Final report will be comprehensive and detailed, and it will include data,
analysis, trends, and other relevant information related to the topic or
2010 2022 2030
3.1.1 Increasing Prevalence of Health Morbidities like Cancer, Chronic & Infectious Diseases. 44% of adults have at
least 1 of 10 common chronic conditions in Canada
Incidence of Diseases in Canada
Illustrative

40
4.1 Market growth drivers (continued)
Top countries that are leveraging
technology in their fight against clinical
diagnostics
United States
Japan
Germany
South Korea
China
United Kingdom
France
Canada
Australia
Israel
Switzerland
Singapore
Sweden
Netherlands
Italy
Spain
Belgium
Denmark
Austria
Norway
3.1.2 Growing awareness about early detection & screening of diseases. The Canadian Task Force on Preventative
Health Care recommends mammogram screening for women over the age of 50
 Canada has a long history of investing in clinical diagnostics
research and treatment, and as a result, has become a
world leader in the field
 IT has a robust healthcare infrastructure, including world-
renowned research institutions, hospitals, and clinics, that
are dedicated to clinical diagnostics treatment and research
 One of the key factors that has allowed Canada to stay
ahead in the field of clinical diagnostics research and
treatment is the high level of investment in clinical
diagnostics-related research
Illustrative

41
4.1 Market growth drivers (continued)
Fundings from government and other
organizations
3.1.3 Government initiatives and investments in increasing number of equipment in diagnostic facility. Venture
capital investment into health diagnostics companies peaked in 2020 with $4.8 Bn going into the sector. Since 2017,
investors have infused nearly $20.3 Bn into this sector
 Canada government provides significant support and
funding for clinical diagnostics research and treatment,
which is driving innovation and growth in the clinical
diagnostics market
 Please be aware that this sample report is intended to
provide you with a brief overview of the kind of information
and analysis that will be presented in the final report
Source Year Fund ($)
National clinical
diagnostics Institute
(NCI)
2021 $ 6.4 Bn
Centers for Disease
Control and
Prevention (CDC)
2021 $ 501 Mn
American clinical
diagnostics Society
(ACS)
2020 $ 150 Mn
Susan G. Komen 2020 $ 98 Mn
Illustrative

42
4.2 Market restraints
3.2.1 Delayed in Diagnosis.
61.6% of Canadians with a mood
and/or anxiety disorder had their
diagnosis more than a year after
symptom onset
 Clinical diagnostics treatments can
be very expensive and can lead to
financial burden for patients and
healthcare systems
 Cost of clinical diagnostics
treatment varies depending on the
type of clinical diagnostics, stage of
clinical diagnostics, and treatment
options
 Some common clinical diagnostics
treatments, such as chemotherapy
and radiation therapy, can cost tens
of thousands of dollars
3.2.2 Shortage of Diagnosis Equipment.
35.5% of Canadian Medical Imaging
equipment is 10 or more years old
 Requirements for clinical
diagnostics treatments can be very
stringent, which can slow down the
approval process and limit access
to new treatments
 Regulatory bodies, such as Canada
Food and Drug Administration
(FDA), require extensive clinical
trials and safety data before
approving new clinical diagnostics
treatments
 This can be a lengthy and costly
process, which can delay the
availability of new treatments for
patients
3.2.3 Data Privacy Concerns. More
than 400 hospitals in Canada and the
US have been subject to ransomware
attacks since the beginning of the
pandemic
 There is a shortage of oncologists
in Canada, which can limit access
to clinical diagnostics treatments
and create barriers to growth in the
clinical diagnostics market
 Oncologists are physicians who
specialize in the diagnosis and
treatment of clinical diagnostics
 With the aging population and the
increasing incidence of clinical
diagnostics, there is a growing
demand for oncologists
 However, the supply of oncologists
is not keeping pace with the
demand
Our analysis will thoroughly investigate the key restraints that may significantly impact business
operations and growth.
Illustrative

5. Competitive Landscape

44
5.1 Major Market Share
XX
Other
 Canada clinical diagnostics market is a
highly competitive space, with many
companies developing and marketing
clinical diagnostics treatments
 Some of the top companies in Canada
clinical diagnostics market based on
revenue and market share include
interest
Revenue of Major players in Canada clinical
diagnostics Market ($ Mn)
Illustrative

45
5.2 Key Company Profile
 Here is the list of top 10 companies which
will cover in the final report
 Each company will have slides for
o Overview
o Key details
o Offerings
o Name of products
o Recent activities/ Press Coverage
o Distribution and Vendor Partners
o Mergers, Acquisitions and
Collaboration
o Financials
 If there are specific companies that you
would like to be included in the report,
please let us know via email
1 Dynacare
3 SickKids
5 Public Health Ontario
7 Akumin Inc
9 EFW Radiology
2
LifeLabs Medical
Laboratory Services
4 MIC Medical Imaging
6 Biron
8 AlphaLabs
Spartan Bioscience:
Key Note:
10

46
5.2.1 Dynacare
Founded in: 1959
HQ: Ontario, Canada
Type: Private
Revenue: $977.9 Mn
Website: www.dynacare.ca
 Dynacare provides a comprehensive variety of laboratory testing
services
 It includes regular and specialized tests in hematology, clinical
chemistry, immunology, and genetics
 It has over 165 patient care centers across Quebec, Ontario,
Manitoba, Alberta and British Columbia in Canada
 Company is owned by Lab Corp, an American company based out
of Burlington, North Carolina
Solutions offered by Dynacare
 Diagnostics
 Community Solutions
 Hospital Solutions
 Dynacare Logistics
Prenatal Tests HPV Testing
Pharmacogenomic Tests Allergy Testing
Pharmacogenomic Tests Cervical Cancer/HPV Testing
QuantiFERON®-TB Testing Hereditary Cancer Screening
Pap Test Heart Health
Services Offered Recent Activity / Press Coverage
The Brampton Board of Trade is delighted to announce that Vito Ciciretto,
President & CEO of Dynacare, has been named 2021 Brampton Business
Person of the Year.
Dynacare, a Labcorp subsidiary and one of Canada’s leading health and
wellness solutions providers, today announced that they have entered into
an agreement to acquire Valley Medical Laboratories in British Columbia
effective May 1, 2023.

47
5.2.1 Dynacare (continued)
Major Companies Major Partners
Partnerships Ecosystem
 Central Medical Laboratories (CML) is
established in Winnipeg, Manitoba.
 CML continues to operate as an
important division in the Dynacare group
of companies
 Bio-Science Laboratory, now part of the
Dynacare Medical Laboratories
partnership
 Gamma-Dynacare Medical Laboratories
created by a partnership between
Dynacare, Gamma North Peel
Partnership and Bio-Science Laboratory
 LabCorp had acquired Dynacare
Laboratories, becoming the majority
shareholder of Gamma-Dynacare
Medical Laboratories
 Dynacare took a strategic move by
introducing a new national healthcare
logistics business - Accuro Health
Services
 Dynacare acquires Lab Bio-Médic, a
privately owned laboratory in Quebec that
provides services to medical clinics,
industries, insurance companies and
clinical research organizations

48
Company Name Type
Amount /
Duration
Year Key Pointers
Acquisition - May, 2023
 Dynacare, a Labcorp subsidiary announced that they have
entered into an agreement to acquire Valley Medical Laboratories
in British Columbia
 The combined strength of Dynacare and Valley Medical will offer
an expansive patient service centre network and diagnostic test
menu to patients, customers, and the healthcare community
Acquisition $488 Mn July 2002
 LabCorp acquired all of the outstanding shares of Dynacare and
financed the transaction
 The first national clinical laboratory to fully embrace genomic
testing, Laboratory Corporation of America(R) Holdings
(LabCorp(R)) has been a pioneer in commercializing new
diagnostic technologies
Important Deals - Mergers and Acquisitions

49
63.3
70.3 70.9
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Revenues ($Bn), 2020-2030
 $977.9 Mn was the revenue generated by
Dynacare in 2022
 They are profitable in a wide range of laboratory
testing services including routine and specialty
tests in areas such as hematology, clinical
chemistry, immunology, molecular diagnostics
and genetics
 Revenue generated by Dynacare in 2020 reflects
the company's continued growth and success in
the healthcare industry
 In order to obtain access to all of the information
that you are seeking, you will need to purchase
the final report
Breakdown of Net Revenue by Segment, 2022
1 2 3 4
Illustrative

50
5.2.2 Company 2
Founded in:
HQ:
Type:
Revenue:
Website:
Solutions offered by Company
Drugs Indications
Drugs for clinical
diagnostics
Recent Activity / Press Coverage
Illustrative

51
5.2.2 Company 2 (continued)
Major Distribution Partners Major Vendor Partners
Partnerships Ecosystem
Illustrative

52
Company Name Type
Amount /
Duration
Year Key Pointers
Latest Deals - Mergers and Acquisitions
Illustrative

53
xx xx xx
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Revenues ($Bn), 2020-2030
report
 In this section you will the understating of
financial overview of the company, which
includes revenue forecasting, segment
revenue and other key details as per
availability
interest
Breakdown of Net Revenue by Segment, 2022
1 2 3 4
Illustrative

6. Reimbursement Scenario

55
6.1 Reimbursement Regulation
The reimbursement scenario in the US clinical diagnostics market is complex and
can vary depending on the specific treatment, setting of care, and insurance
coverage. Here are some key points to consider:
 Medicare:
o Medicare is a federal health insurance program for people aged 65 and
older, as well as people with certain disabilities or health conditions
o Medicare covers many clinical diagnostics treatments, including
chemotherapy, radiation therapy, and some immunotherapies
o However, coverage can be subject to strict guidelines and restrictions,
such as the requirement for prior authorization
 Medicaid:
o Medicaid is a joint federal-state program that provides health insurance
for people with low incomes
o Medicaid coverage for clinical diagnostics treatments can vary by state,
and may be subject to limits on the amount and type of treatment
covered
 Private Insurance:
o Private insurance coverage for clinical diagnostics treatments can also
vary widely depending on the insurer and the specific policy
o Some policies may have high out-of-pocket costs, such as deductibles
and co-pays, while others may have more comprehensive coverage
Medicare and Medicaid together provide
health insurance coverage for more than
4 in 10 Americans
Medicare
17%
Medicaid
and CHIP
21%
Employer-Sponsored
49%
Other Private
3%
Other Public
1%
Uninsured
9%
Health Insurance Coverage, 2022
Illustrative

56
6.1 Reimbursement Regulation (continued)
 Affordable Care Act:
o Affordable Care Act (ACA) includes provisions to help improve access to clinical diagnostics treatments by requiring insurers
to cover certain preventive services, including clinical diagnostics screenings, without co-pays or deductibles
o It also includes protections for people with pre-existing conditions, such as clinical diagnostics
 Reimbursement for New Treatments:
o Reimbursement for new clinical diagnostics treatments can be a complex and lengthy process, as insurers and government
programs often require evidence of safety and effectiveness before providing coverage
o This can create challenges for companies developing and marketing new treatments
 Value-Based Care:
o There is a growing trend towards value-based care, which aims to improve outcomes and lower costs by focusing on the
value of treatments rather than simply the volume of treatments
o Value-based care models can include payment models that tie reimbursement to outcomes or performance metrics
In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the
topic or subject matter of interest
Illustrative

57
6.1 Reimbursement Regulation (continued)
Coverage Penetration (% Total Population) Source of Funding
Spend on Healthcare (%of Current Health Expenditure)
Reimbursement Market Trends
 Public healthcare coverage is provided by the government and includes programs like
Medicare and Medicaid
 Medicare is a federal program that provides healthcare coverage to individuals who
are 65 years of age or older, as well as certain younger people with disabilities
 Medicaid is a joint federal-state program that provides healthcare coverage to
individuals with low income and limited resources
 Shift towards value-based care has been a significant trend in the US healthcare system, with payers and providers increasingly focused on improving patient
outcomes and reducing costs
 This has led to the development of alternative payment models such as accountable care organizations (ACOs) and bundled payment arrangements, which
incentivize providers to deliver high-quality, cost-effective care 38.9%
37.1%
35.6%
32.5%
31.5%
44.0%
46.0%
47.7%
51.0%
51.8%
2017 2018 2019 2020 2021 2022 2023
Government Expenditure
Private Health Insurance
Out of Pocket
Other
NA NA
100% 100% 100% 100% 100%
xx xx xx xx xx
2012 2013 2014 2015 2016
Public Healthcare
Coverage
Private Coverage
6.3% 4.08% 5.1% 3.8% 2.2% 2.4% 3.6% GDP Growth (yoy)
14.7% 11.3% 15.5% 7.5% 4.2% NA NA HC Spend Growth (yoy)
Illustrative

58
6.2 Reimbursement Process for Clinical Diagnostics
The reimbursement process in the US healthcare system can be complex and can vary depending on the type of healthcare service,
the healthcare provider, and the insurance coverage. Here are the general steps involved in the reimbursement process:
 Service or Treatment Provided: The healthcare provider performs a service or treatment for the patient
 Billing: The healthcare provider submits a claim to the insurance company or other payer, requesting reimbursement for the
service provided
 Adjudication: The insurance company or other payer reviews the claim to determine whether it meets the criteria for
reimbursement. This can involve verifying the patient's eligibility, reviewing the treatment provided, and checking for any potential
errors or fraud
 Payment: If the claim is approved, the insurance company or other payer reimburses the healthcare provider for the service
provided, based on the negotiated payment rates or fee schedule
 Patient Responsibility: Depending on the patient's insurance coverage, they may be responsible for paying a portion of the cost
of the service, such as deductibles, co-payments, or co-insurance
In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the
topic or subject matter of interest
Illustrative

59
6.3 Reimbursement Process - Medicare
Medicare
Population Covered
 100% population is covered under this scheme
 Citizen’s contribute to this scheme which then earns an interest. There is Basic Healthcare Sum (BHS) cap which limits the maximum contribution to an
individuals Medicare account
Provider Restrictions/
Selection
Services can be claimed from Medicare-approved institutions only (14 public hospitals, 10 private hospitals, 7 public community centers, 1 private community
center and over 100 surgery centers, dialysis centers, colonoscopy centers and screening centers)
Services Covered
 Medicines under SDL and MAF Plus can be bought from the money saved in this account
 Money can be also be claimed for antiretroviral drugs for HIV, Desferrioxamine drug for treatment of thalassemia and immuno-suppressant drugs for organ
transplant
 Money from this account can be used to pay Medishield premiums and Integrated Shield Plan premiums, subject to withdrawal limits
 Patients above 65 years of age can claim under Flexi-Medicare and further reduce their out-of-pocket expenses by using up to $200 per patient per year from
their Medicare account
 Excluded: Traditional drugs such as Herbal and Ayurveda cannot be claimed from Medicare account; Drugs used for cosmetic purposes such as slimming pills
and hair loss pills cannot be claimed from this account
Level of Coverage/ Assurance
 Approved chronic conditions and vaccinations, health screenings as outpatient treatments can be paid with Medicare up to $500 per account per year, however
a cash copayment of 15% is applicable
 Inpatient hospitalization, up to $450 per day + surgical limits according to Table of Surgical Procedures
 Approved day surgeries up to $300 per day + surgical limits according to Table of Surgical Procedures
 Outpatient scans/ diagnostics for clinical diagnostics up to $600 per year per patient, and up to $300 for other medical conditions
 Chemotherapy (includes analgesic medication and suppressive treatments such as neuroendocrine and nuclear medicine treatments) up to $1,200 per month
per patient
 Renal dialysis up to $450 per patient per month
 Other treatments are also approved with various sub-limits for withdrawal
Mechanism of Coverage
 DRG with Activity Based Funding for public providers
 Block funding with DRG for providers not covered under ABF
Financial Feasibility  The Basic Healthcare sum has been increased by more than 4.4% in 2017 on account of increasing costs of healthcare. This is an individual account
Illustrative

60
6.4 Reimbursement Process - Medicaid
Medicaid
Population Covered
 38% population is covered under this scheme
 Medicare covers individuals who are aged 65 and older, as well as those with certain disabilities or end-stage renal disease
Provider Restrictions/
Selection
Services can be claimed from Medicaid-approved institutions only (14 public hospitals, 10 private hospitals, 7 public community centers, 1 private community
center and over 100 surgery centers, dialysis centers, colonoscopy centers and screening centers)
Services Covered
 Medicines under SDL and MAF Plus can be bought from the money saved in this account
 Money can be also be claimed for antiretroviral drugs for HIV, Desferrioxamine drug for treatment of thalassemia and immuno-suppressant drugs for organ
transplant
 Money from this account can be used to pay Medishield premiums and Integrated Shield Plan premiums, subject to withdrawal limits
 Patients above 65 years of age can claim under Flexi-Medicaid and further reduce their out-of-pocket expenses by using up to $200 per patient per year from
their Medicaid account
 Excluded: Traditional drugs such as Herbal and Ayurveda cannot be claimed from Medicaid account; Drugs used for cosmetic purposes such as slimming pills
and hair loss pills cannot be claimed from this account
Level of Coverage/ Assurance
 Approved chronic conditions and vaccinations, health screenings as outpatient treatments can be paid with Medicaid up to $500 per account per year, however
a cash copayment of 15% is applicable
 Inpatient hospitalization, up to $450 per day + surgical limits according to Table of Surgical Procedures
 Approved day surgeries up to $300 per day + surgical limits according to Table of Surgical Procedures
 Outpatient scans/ diagnostics for clinical diagnostics up to $600 per year per patient, and up to $300 for other medical conditions
 Chemotherapy (includes analgesic medication and suppressive treatments such as neuroendocrine and nuclear medicine treatments) up to $1,200 per month
per patient
 Renal dialysis up to $450 per patient per month
 Other treatments are also approved with various sub-limits for withdrawal
Mechanism of Coverage
 DRG with Activity Based Funding for public providers
 Block funding with DRG for providers not covered under ABF
Financial Feasibility  The Basic Healthcare sum has been increased by more than 4.4% in 2017 on account of increasing costs of healthcare. This is an individual account
Illustrative

Life-sciences Market Research
Reports you can trust
www.insights10.com
We maintain an extensive database comprising
over 30,000 syndicated market research reports
within the pharmaceuticals and healthcare sector,
offering a global, regional, and country-level
perspective. Our services also include the provision
of customized research reports, meticulously
tailored to align with your specific requirements.

At Insights10, our extensive report
library spans a diverse range of
categories within the field of life
sciences.
Market Research
Reports across various
categories in healthcare
www.insights10.com
Digital
Health
Medical
Devices
Healthcare
Services
Rare
Diseases
Clinical
Trials
OTC &
Nutraceuticals
Pharma
(Diseases
& Drugs)

Click on the country to see the reports
available
Global Coverage
North America
• US
• Canada
Latin America
• Brazil
• Argentina
• Mexico
• Ecuador
• Venezuela
• Senegal
Europe
• UK
• Germany
• France
• Italy
• Spain
• Russia
• Netherlands
• Sweden
• Romania
• Switzerland
• Poland
• Austria
• Ireland
• Norway
• Denmark
• Belgium
• Portugal
• Ukraine
• Bulgaria
• Finland
APAC
• India
• China
• South Korea
• Japan
• Australia
• Indonesia
• Hong Kong
• New Zealand
• Philippines
• Singapore
• Malaysia
• Thailand
• Vietnam
Middle East
• UAE
• Saudi Arabia
• Turkey
• Lebanon
• Kuwait
• Qatar
Africa
• Egypt
• Kenya
• South Africa
• Algeria
• Nigeria
• Libya
• Tanzania
• Morocco

What do our reports cover?
Market Overview
Growth Drivers & Growth Restraints
Epidemiology & Disease type
Market Size & Forecast
Competitive Landscape
Policy & Regulatory Landscape
Reimbursement Scenario
Recent Developments
Market Segmentation Factors Driving Future Growth
1
2
3
4
5
6
7
8
9
10

01 03
02 04 05
Define
precise
research
questions
Validate data
through primary
research
interviews
Gather data
through
secondary
research
Forecast
market size
and segment
analysis
Extract key
insights from
the research
findings
06
Compile &
present a
comprehensive
analytical report
Our Research Process

Bottom Up Approach
Analyze product or treatment pricing
and reimbursement strategies
Evaluate consumer or patient
demographics and numbers
Predict future market
growth or decline based
on key market trends &
dynamics
Find
final
market size
Top Down Approach
Examine the total healthcare expenditure in
the targeted disease or service domain.
Assess the proportion of spending
allocated to the specific product or
treatment category.
Predict future market
growth or decline
based on key market
trends & dynamics
Find
final
market
size
Data Triangulation & Data Validation

2022
2023-
2030
Report Attribute
Quantitative Units
Pricing and Purchase
Revenue in USD Million/Billion (Mn/Bn)
Our pricing and purchase options are adaptable to
suit the specific scope of work.
Details
Time Frame
Base
Year for
estimation
Forecast
Period
Report Scope
Delivery Timeline
Typically, the delivery of the final report falls within a
timeframe of 5 to 7 business days, but the exact
duration may vary depending on the project's scope.
Customization
We are pleased to offer you the option of
customizing the report to align with your specific
research requirements at no extra charge, provided
it falls within the defined scope of the project.

We have access to a multitude of highly
dependable data sources, supported by
years of experience that guide us in
discerning which sources are most reliable
and current for the specific information
needed.
Access to credible
data sources for
secondary research
www.insights10.com
Statistical
Databases
Annual
Reports
Trade
Publications
Online
Databases
Published
Research
Reports
White-
papers
Press
Releases

Reliable
Expert Verified
Realistic
Comprehensive
Easy to read
Our reports present data, which is
The report is prepared using a proven methodology and insightful
research
The report is prepared by a team of highly qualified & experienced
research analysts & vetted by our local associates
The report allows you to confidently make smarter business and
strategic decisions based on realistic findings
Covers everything you would need to know about the market
including market size, competitive analysis & much more
You do not have to be a market expert to understand what really is
happening on the market and how it works

Yearly Access
(Subscription)
Regulatory
Compliance
Competitive
Intelligence
Conference
Coverage
Full-Time
Engagement
Database Service
& KOL Mapping
Primary Research &
Interviews
Customized Market
Research Reports
Syndicated Market
Research Reports
Our Services

“The business decision-making process is no longer as
straightforward as it used to be. It requires insights
generated at the right time, based on reliable data
interpreted in a nuanced manner for each market. We at
Insights10 are building the future of market research and
are committed to providing our clients with the right
intelligence and insights to make business decisions
quickly and efficiently.
Insights10 is a unique platform that combines deep
domain expertise, nuanced data at a country and
functional area level, and years of experience working with
some of the best organizations in the world, generating
insights that provides substantial competitive advantage.”
Dr. Purav Gandhi, Founder & CEO
Click to watch Our Introductory Video here
CEO Speaks

Purav is a physician and an
entrepreneur with 12+ years of
experience in Healthcare & Life
Sciences industry spanning across
strategy, market access, health
informatics and RWE, digital health,
analytics and data science. Purav
studied medicine from Gujarat
University and also completed his MBA
from IIM-Kozhikode. Purav started his
career with Deloitte working on strategy
consulting engagements and also co-
founded ConvergeHealth by Deloitte.
Anish has 15+ years of
experience in management
consulting in the Life Sciences
sector, and has worked with
diverse multinational firms in
the US, India, Middle East and
APAC regions. His primary area
of interest is Customer and
Market Strategy, Market
Access, and Digital Health with
special focus on emerging
markets like Africa, Middle East
and APAC.
Dr. Purav Gandhi
Founder & CEO
Anish Swaminathan
Director
Mukesh is an engineering graduate with
an MBA in Marketing. He is a seasoned
healthcare market research &
marketing professional with a
progressive experience of over 20
years in Life Sciences, Healthcare
services, Pharma and Medical Device
sectors. With an in-depth understanding
of primary research, he has conducted
hundreds of interviews of various
stakeholders in pharma & healthcare &
completed several research projects
across life sciences industry.
Ritu has over 6 years of experience in
strategy building, market assessments,
market sizing, and RWE for global MNC
healthcare & biopharma clients across
diff. markets (America, Europe, Africa,
APAC and Middle East). Her areas of
expertise include: Indentifying emerging
trends in life sciences industry,
Competitor landscape assessment,
Disease opportunity assessments etc.
She is a pro in secondary and primary
research with a deep domain expertise
in healthcare sector.
Mukesh Nayak
Head – Marketing & Research
Ritu Baliya
Engagement Manager
Leadership Team

… and many more
Pi-SM
GmbH
Our Clients

I've had the pleasure of availing Insights10’s services several times, and I've always
been impressed by their expertise, professionalism, and dedication to providing us with
the highest quality data and insights. Whether one is looking to launch a new product,
expand into a new market, or better understand one's target customers, Insights10
insures achieving the goals.
Their team of experts has a deep understanding of the healthcare industry, and they use
their knowledge to develop customized research solutions that meet the specific needs
of each client. I highly recommend Insights10 to anyone looking for a reliable and
experienced partner in healthcare market research. They're a valuable asset to any
company that wants to succeed in this dynamic sector.
Sid Panigrahy
Founder-CEO, MediGlobo Inc.,
(Healthcare - Group Company of Omi Holdings, Inc) Tampa, Florida (USA)
What our clients say

Dear Insights10 Team, I wanted to thank you all for the great work you conducted
producing the Kenya Medical and Diagnostic Laboratory Service Market Analysis. The
quality of the report was excellent, and you managed to complete it in record time. I was
also impressed by your quick turnaround on the topics discussed as a follow up after the
report's first version; you managed to gather the information required, plus a very good
analysis.
I will definitely consider working with you again if the opportunity arises, and will not
hesitate in recommending you to colleagues working in the field Thank you again for
your professionalism and team work. It was a pleasure working with you.
Lelio Marmora
CEO, The Management Lab, Geneva
Ex. Executive Director, UNITAID

Michael Blumberg Youssef Mallat
Wissem Menad
Dr. Robert Ryan
Co Founder GFAU Pty Ltd., Australia
Co Founder – Embi, Optimum Oral care, Australia
Opusline, A part of Accenture, Paris
Senior Manager Segment Marketing
Performance Health, London, UK
Chief Executive Officer, Innova Therapeutics, Inc., USA
We engaged INSIGHTS10 to assist us with our research requirements
for the Oral Care Market sector in Australia. We been very impressed
with the depth and quality of data and equally with the personal
service we experience from the management team on our account.
They understand our business, our challenges and our goals. There is
a real sense of partnership as we continue to work together.
The info you delivered on the European Patient
Support Market with a deep dive into countries
like Spain, Germany, Italy, France, UK and
Belgium, was very useful.
Insights10 has been a great resource for
getting a detailed report on the UK
Physiotherapy Market. Usually I had multiple
sources for getting global reports, but now I
can get in-depth country reports from
Insights10 which has been a game changer.
We were looking for very specific information regarding Abu Dhabi
Oncology Drugs Market. The insights provided by Insights10 is
fantastic and they just took less than three days to deliver the report.

Thank You
www.insights10.com
Email: insights@insights10.com
India: (+91) 931 639 7935
We would be happy to help.
Do you have
any questions?

Canada Clinical Diagnostics Market Sample Report 2022 to 2030

Recommended

Recommended

More Related Content

Similar to Canada Clinical Diagnostics Market Sample Report 2022 to 2030

Similar to Canada Clinical Diagnostics Market Sample Report 2022 to 2030 (20)

More from Insights10

More from Insights10 (9)

Recently uploaded

Recently uploaded (20)

Canada Clinical Diagnostics Market Sample Report 2022 to 2030